Historical Valuation
bioAffinity Technologies Inc (BIAF) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.83 is considered Undervalued compared with the five-year average of -1.93. The fair price of bioAffinity Technologies Inc (BIAF) is between 516.76 to 519.15 according to relative valuation methord. Compared to the current price of 1.29 USD , bioAffinity Technologies Inc is Undervalued By 99.75%.
Relative Value
Fair Zone
516.76-519.15
Current Price：1.29
99.75%
Undervalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
bioAffinity Technologies Inc (BIAF) has a current Price-to-Book (P/B) ratio of 0.47. Compared to its 3-year average P/B ratio of 2.60 , the current P/B ratio is approximately -81.74% higher. Relative to its 5-year average P/B ratio of 2.44, the current P/B ratio is about -80.55% higher. bioAffinity Technologies Inc (BIAF) has a Forward Free Cash Flow (FCF) yield of approximately -155.23%. Compared to its 3-year average FCF yield of -55.53%, the current FCF yield is approximately 179.57% lower. Relative to its 5-year average FCF yield of -51.30% , the current FCF yield is about 202.60% lower.
P/B
Median3y
2.60
Median5y
2.44
FCF Yield
Median3y
-55.53
Median5y
-51.30
Competitors Valuation Multiple
AI Analysis for BIAF
The average P/S ratio for BIAF competitors is 1436.92, providing a benchmark for relative valuation. bioAffinity Technologies Inc Corp (BIAF.O) exhibits a P/S ratio of 0.83, which is -99.94% above the industry average. Given its robust revenue growth of -38.48%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for BIAF
1Y
3Y
5Y
Market capitalization of BIAF increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of BIAF in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is BIAF currently overvalued or undervalued?
bioAffinity Technologies Inc (BIAF) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.83 is considered Undervalued compared with the five-year average of -1.93. The fair price of bioAffinity Technologies Inc (BIAF) is between 516.76 to 519.15 according to relative valuation methord. Compared to the current price of 1.29 USD , bioAffinity Technologies Inc is Undervalued By 99.75% .
What is bioAffinity Technologies Inc (BIAF) fair value?
BIAF's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of bioAffinity Technologies Inc (BIAF) is between 516.76 to 519.15 according to relative valuation methord.
How does BIAF's valuation metrics compare to the industry average?
The average P/S ratio for BIAF's competitors is 1436.92, providing a benchmark for relative valuation. bioAffinity Technologies Inc Corp (BIAF) exhibits a P/S ratio of 0.83, which is -99.94% above the industry average. Given its robust revenue growth of -38.48%, this premium appears unsustainable.
What is the current P/B ratio for bioAffinity Technologies Inc (BIAF) as of Jan 10 2026?
As of Jan 10 2026, bioAffinity Technologies Inc (BIAF) has a P/B ratio of 0.47. This indicates that the market values BIAF at 0.47 times its book value.
What is the current FCF Yield for bioAffinity Technologies Inc (BIAF) as of Jan 10 2026?
As of Jan 10 2026, bioAffinity Technologies Inc (BIAF) has a FCF Yield of -155.23%. This means that for every dollar of bioAffinity Technologies Inc’s market capitalization, the company generates -155.23 cents in free cash flow.
What is the current Forward P/E ratio for bioAffinity Technologies Inc (BIAF) as of Jan 10 2026?
As of Jan 10 2026, bioAffinity Technologies Inc (BIAF) has a Forward P/E ratio of -0.13. This means the market is willing to pay $-0.13 for every dollar of bioAffinity Technologies Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for bioAffinity Technologies Inc (BIAF) as of Jan 10 2026?
As of Jan 10 2026, bioAffinity Technologies Inc (BIAF) has a Forward P/S ratio of 0.83. This means the market is valuing BIAF at $0.83 for every dollar of expected revenue over the next 12 months.